
Up to one half of adults with inflammatory bowel disease (IBD) have musculoskeletal pain which can significantly impact their function and quality of life. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used to treat musculoskeletal symptoms, but there are mixed safety data as to whether these drugs may actually trigger IBD flares - a concern reflected in clinical recommendations from the American College of Gastroenterology.
Now a new retrospective analysis from nearly 350,000 patients over a span of more than two decades indicates that NSAIDs may be a viable clinical option for select patients with IBD on a case-by-case basis.
The statistical findings are published in the journal Arthritis Care and Research, and the paper is an “editor’s choice” for November 2026. The first author is Adam Mayer, M.D., M.S.C.E., assistant member of the Hackensack Meridian Center for Discovery and Innovation (CDI), and assistant professor of Internal Medicine and Pediatrics at the Hackensack Meridian School of Medicine, who collaborated with colleagues from the University of Pennsylvania and the Children Hospital of Philadelphia.
The analysis encompassed administrative claims data from adult patients with IBD from Optum’s de-identified Clinformatics Data Mart Database, spanning the years 2000 through 2022. Over 80,000 patients who received NSAIDs were compared with those who did not take the drugs for the risk of IBD-related hospitalizations. The statistical models were weighted for propensity for NSAID use, using inverse probability of treatment-weighted Cox proportional hazard models.
Prescription NSAID use was associated with a small increase in IBD-related hospitalization for the entire group of patients. But the results also demonstrated “non-inferiority,” meaning that the using drugs was not necessarily a less-good clinical decision, based on outcomes. For the ulcerative colitis group, there was even more good news: the use of NSAIDs did not demonstrate a significantly increased risk of IBD-related hospitalization. Conversely, the subgroup diagnosed with Crohn’s disease had less promising results. Patients with Crohn's disease had a significantly increased risk of IBD-related hospitalization and did not meet the threshold for non-inferiority.
“These results suggest that NSAID use may be acceptable for select patients with IBD who have significant musculoskeletal symptoms, especially those with ulcerative colitis,” write the authors. “Although further prospective study of NSAID safety in IBD is needed, the findings in this study suggest that the risk of NSAID exposure may be acceptable in select cases with strong indications for this use, such as those with significant musculoskeletal disease.”
